Mode
Text Size
Log in / Sign up

Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis

Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast …
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider curative-intent local therapy for isolated contralateral axillary metastasis, recognizing observational design limits causal inference.

This retrospective cohort study pooled 1110 patients from two tertiary centers across three cohorts: isolated contralateral axillary metastasis (CAM, n=128), stage IIIC locally advanced breast cancer (LABC, n=532), and de novo oligometastatic (M1, n=450) disease. Overall survival was compared using Kaplan-Meier methods and multivariable Cox regression. Within the CAM cohort, propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and multivariable Cox models were used to compare curative-intent local therapy (surgery/radiotherapy) against a systemic therapy-focused approach.

Adjusted mortality risk for the CAM cohort was significantly lower than for the M1 cohort (aHR 0.58, 95% CI 0.45–0.74) but numerically higher than for the LABC cohort (aHR 1.18, 95% CI 0.93–1.60), positioning CAM prognostically between locoregional and metastatic disease. In the PSM analysis within CAM, curative-intent local therapy was associated with a 51% reduction in mortality risk (HR 0.49, 95% CI 0.31–0.78) and a significantly lower 5-year cumulative incidence of locoregional recurrence (12.1% vs 31.4%, p=0.005). Findings were consistent across IPTW and multivariable analyses.

Safety, adverse event, and follow-up duration data were not reported in the abstract. As a retrospective observational cohort, the analysis remains vulnerable to residual confounding and selection bias despite PSM and IPTW adjustment, and causal inference is limited. The authors conclude that isolated CAM is prognostically distinct from classic stage IV disease and support re-evaluation of CAM as a regionally treatable entity potentially amenable to curative-intent local therapy rather than default palliative systemic management.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundContralateral axillary metastasis (CAM) is currently staged as M1 (stage IV) breast cancer, guiding treatment towards palliative systemic therapy. However, emerging evidence suggests CAM may behave as a locoregional event, potentially amenable to curative-intent strategies. This study aims to define the prognosis of isolated CAM and evaluate the survival impact of aggressive local therapy.MethodsWe conducted a retrospective cohort study of 1110 patients from two tertiary centers, comprising three cohorts: CAM (n=128), stage IIIC locally advanced breast cancer (LABC, n=532), and de novo oligometastatic (M1, n=450) disease. Overall survival (OS) was compared using Kaplan-Meier and multivariable Cox regression. Within the CAM cohort, we employed propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and multivariable Cox models to compare outcomes between patients receiving curative-intent local therapy (surgery/radiotherapy) versus a systemic therapy-focused approach.ResultsThe adjusted mortality risk for the CAM cohort was significantly lower than for the M1 cohort (aHR 0.58, 95% CI 0.45–0.74) but higher than for the LABC cohort (aHR 1.18, 95% CI 0.93–1.60). In the PSM analysis, curative-intent therapy was associated with a 51% reduction in mortality risk (HR 0.49, 95% CI 0.31–0.78) and a significantly lower 5-year cumulative incidence of locoregional recurrence (12.1% vs. 31.4%, p=0.005). Results were consistent across IPTW and multivariable analyses.ConclusionPatients with isolated CAM exhibit a prognosis distinct from classic stage IV disease. A curative-intent local treatment strategy is independently associated with significantly improved survival and locoregional control, supporting the re-evaluation of CAM as a clinically regionally treatable entity.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.